🧬 BioMed Pulse · 2026-11-06 02:01 UTC

BIOMED PULSE

Friday, November 6, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has now spread to Nigeria and Kenya alongside Uganda, making it the largest Ebola-family outbreak ever recorded in the DRC with sustained, high-level transmission across multiple provinces. Mood: grave — a slow-moving catastrophe is accelerating geographically while several other simultaneous outbreaks stretch global response capacity.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA FAMILY) — DRC, UGANDA, KENYA, NIGERIA

  • As of October 23, 2026, the WHO Disease Outbreak News (DON-622) confirmed Bundibugyo virus disease (BVD) has now exported cases to both Kenya and Nigeria in addition to Uganda, marking a significant geographic escalation. [1]
  • The outbreak, which began in Mongbwalu health zone, Ituri Province, DRC, on May 15, 2026, is now the largest Ebola outbreak ever reported in the DRC, per WHO DON-617. [2]
  • As of September 25, 2026 (DON-621), the outbreak had reached the new province of Sud Ubangi in the northwest DRC, spreading to 63 health zones across at least 7 provinces including Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, Tshopo, and now Sud Ubangi. [3]
  • By July 15 (DON-613), cumulative confirmed cases stood at 2,124 including 828 deaths, representing a case fatality rate approaching 39 percent among confirmed cases. [4]
  • CDC mobilized an Ebola response on May 17, 2026, expanded airport entry screening to Washington-Dulles on May 21 and Atlanta on May 23, and has issued daily transcript briefings. [5] [6] [7]

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIAN FEDERATION

  • On October 2, 2026, WHO was notified via media reports of the death of an employee of the Irkutsk Antiplague Research Institute (APRI) of Siberia and the Far East, following severe pneumonia of unknown cause. [8]
  • The setting — a biosafety research institute — elevates the significance of the case; WHO is investigating and the etiology remains undetermined as of the October 10 DON-620 report. [8]

MERS-COV — KINGDOM OF SAUDI ARABIA

  • Between January 1 and October 5, 2026, Saudi Arabia reported 8 laboratory-confirmed MERS-CoV cases including 1 death, detected across six locations: Al Jouf, Arar, Hafr Al-Batin, Riyadh (2 cases), Tabuk, and one additional site. [9]
  • MERS-CoV transmission remains largely tied to dromedary camel exposure in the Arabian Peninsula with no evidence of sustained human-to-human spread in this cluster. [9]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-LOCATIONS

  • WHO DON-611 (July 2, 2026) confirmed this is the fifth update on the Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship, first notified to WHO on May 2, 2026, involving severe acute respiratory illness cases on board. [10]
  • CDC provided ongoing response transcripts through late June 2026, confirming the U.S. government was actively monitoring American travelers affected; the cruise ship-linked cluster represents a rare documented multi-country ANDV event.

NIPAH VIRUS — INDIA

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district, Kerala, India (WHO DON-609).
  • The patient, an adult male, developed symptoms May 30, was hospitalized June 10 with neurological presentation, consistent with prior Kerala NiV outbreaks traced to Pteropus fruit bats.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections (WHO DON-610), with transmission activity carrying over from an elevated 2025 season in the Americas.
  • Yellow fever is mosquito-borne and preventable by vaccine; the WHO urges travelers to endemic areas in Africa and the Americas to confirm vaccination status.

RABIES — UNITED STATES

  • CDC issued a statement on September 10, 2026, noting a sharp increase in animal rabies activity and associated human exposures nationwide, prompting heightened public awareness.
  • Rabies post-exposure prophylaxis (PEP) remains nearly 100 percent effective when administered promptly following confirmed animal exposure.

DRUG-RESISTANT BACTERIA — UNITED STATES

  • A September 23, 2025 CDC report found a dramatic increase in a dangerous category of drug-resistant bacteria, compounding the antimicrobial resistance threat already noted in the CDC's broader surveillance infrastructure.
  • Separately, the CDC has flagged extensively drug-resistant Salmonella linked to moringa powder capsules (February 2026), with three hospitalizations reported in that cluster.

🧬 LONGEVITY & AGING

EQUOL AND ARTERIAL STIFFNESS — NIH-FUNDED MULTICENTER TRIAL

  • The ACE Trial (NCT05741060), funded by the National Institute on Aging and NIH, is evaluating whether the dietary supplement Equol — a soy isoflavone metabolite — can slow progression of arterial stiffening, small vessel brain disease, and memory decline in healthy volunteers.
  • Arterial stiffness is a well-established independent predictor of cardiovascular mortality and cognitive decline with age, making this a directly longevity-relevant endpoint.

JNJ-63733657 FOR EARLY ALZHEIMER'S DISEASE — JANSSEN / JOHNSON AND JOHNSON

  • Trial NCT04619420 is evaluating JNJ-63733657 versus placebo in participants with early Alzheimer's disease, measuring clinical decline via the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and daily function.
  • The iADRS composite endpoint is increasingly preferred in early-stage Alzheimer's trials because it captures both functional and cognitive trajectories simultaneously.

ALPHA-LIPOIC ACID PLUS MIRABEGRON FOR OBESITY — NIH TRIAL

  • Trial NCT05713799 is testing the combination of mirabegron (a beta-3 adrenergic receptor agonist) and alpha-lipoic acid (ALA, a mitochondrial antioxidant) in both women and men with obesity, targeting metabolic pathways implicated in age-related metabolic decline.
  • Obesity drives at least 2.8 million deaths annually worldwide, and few widely available pharmacological options target its underlying metabolic dysfunction without significant side effects.

COGNITIVE TRAINING FOR MILD COGNITIVE IMPAIRMENT — TELEHEALTH PILOT

  • Trial NCT07366346 is developing a five-week virtual cognitive training intervention for people with Mild Cognitive Impairment (MCI), condensed from an existing eight-week protocol, to assess whether shorter telehealth-delivered training preserves cognitive benefits and improves access.
  • MCI is a recognized intermediate stage between normal aging and dementia, making accessible intervention tools a priority for aging populations.

VITAMIN E METABOLISM AND HYPERLIPIDEMIA — NIH STUDY

  • Trial NCT07715890 is investigating whether elevated blood lipid levels in obesity block vitamin E (a fat-soluble antioxidant) from reaching tissues that need it, potentially explaining part of obesity's link to metabolic disease and accelerated aging.
  • This mechanism — nutrient sequestration by excess circulating lipids — is a novel angle on why obese individuals may show signs of micronutrient insufficiency despite adequate dietary intake.

CANCER MORTALITY PROGRESS — U.S. ANNUAL REPORT

  • The 2026 Annual Report to the Nation on Cancer, released September 22, 2026, showed that progress against lung cancer is driving down overall U.S. cancer mortality rates, a key longevity signal given that cancer remains a leading cause of life-years lost.
  • Falling lung cancer death rates are attributed primarily to decades of reduced smoking prevalence and advances in early detection and targeted therapies.

YOUTH HEALTH TRENDS — CDC 2026

  • CDC data released September 21, 2026, show encouraging progress in youth health metrics, while kindergarten vaccination coverage showed a slight 0.1 percent decline as of the August 2026 report.

💊 NEW CURES & APPROVALS

FDA SUPPLEMENTAL AND ORIGINAL APPROVALS — RECENT ACTIVITY

  • Avyxa Holdings LLC received an original FDA approval (ORIG AP) for Cisplatin (NDA220748), the classic platinum-based chemotherapy agent, under a new application — notable because cisplatin remains a backbone of treatment for testicular, bladder, and ovarian cancers.
  • Nanjing King Friend received an original approval (ORIG AP) for Calcitonin Salmon (ANDA216996), a peptide hormone used to treat osteoporosis and Paget's disease by inhibiting osteoclast-mediated bone resorption — relevant to aging bone health.
  • Axsome Therapeutics received a supplemental approval (SUPPL AP) for Auvelity (NDA215430), containing bupropion hydrochloride and dextromethorphan hydrobromide, a dual-mechanism antidepressant that acts on NMDA receptors and reuptake pathways for treatment of major depressive disorder.
  • Teva Pharmaceuticals received an original tentative approval (ORIG TA) for a generic of Olanzapine and Samidorphan (ANDA220379), the atypical antipsychotic combination that reduces olanzapine-associated weight gain via mu-opioid receptor antagonism by samidorphan.
  • Novartis received a supplemental approval for PIQRAY (alpelisib, NDA212526), a PI3K alpha inhibitor used in PIK3CA-mutated hormone receptor-positive breast cancer — an increasingly common indication with aging relevance given breast cancer's age-related incidence rise.
  • Sun Pharma Global received a supplemental approval for ILUMYA (tildrakizumab-asmn, BLA761067), an IL-23 p19 subunit inhibitor indicated for moderate-to-severe plaque psoriasis.
  • Sandoz and Noven each received supplemental approvals for estradiol transdermal products (VIVELLE NDA020323 and MINIVELLE NDA203752), used in menopausal hormone therapy, which has ongoing relevance in longevity and bone/cardiovascular aging discussions.

🧪 CLINICAL TRIALS

NEMTABRUTINIB FOR COVALENT BTK-REFRACTORY CLL/SLL — NCI

  • Trial NCT07796373, registered November 5, 2026, is evaluating nemtabrutinib — a non-covalent BTK inhibitor — in patients with chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL) who have failed both covalent BTK inhibitors and the reversible BTK inhibitor pirtobrutinib, and have also received a BCL2 inhibitor.
  • Nemtabrutinib's non-covalent binding mechanism is designed to overcome C481S and other resistance mutations that render ibrutinib and acalabrutinib ineffective.

JNJ-63733657 IN EARLY ALZHEIMER'S — JANSSEN

  • Trial NCT04619420 remains active, measuring iADRS composite outcomes; this tau-targeting antibody aims to reduce spread of pathological tau protein, a core driver of Alzheimer's neurodegeneration.

AFIMKIBART (RO7790121) FOR PEDIATRIC CROHN'S DISEASE — PHASE III

  • Trial NCT07298421 is a double-blind, multicenter phase III treat-through study by Roche evaluating afimkibart (RO7790121) for induction and maintenance in children with moderately to severely active Crohn's disease.

CANCER LYSATE VACCINE PLUS IL-15 SUPER-AGONIST N-803 FOR NSCLC — NCI

  • Trial NCT05642195 is evaluating a cancer lysate vaccine with Montanide ISA-51 VG adjuvant, with or without the IL-15 super-agonist N-803, as adjuvant therapy for PD-L1 negative non-small cell lung cancer following surgery.
  • IL-15 super-agonists like N-803 (nogapendekin alfa inbakicept) amplify NK and CD8 T cell responses, potentially compensating for the lack of PD-L1 checkpoint vulnerability in this subgroup.

IL-12 GENETICALLY ENGINEERED MYELOID CELLS — NCI SOLID TUMOR STUDY

  • Trial NCT07672483 is testing IL-12-producing genetically engineered myeloid cells (IL-12 GEMys) in participants with relapsed or refractory solid tumors, leveraging myeloid cells' natural tumor-homing behavior to deliver localized IL-12 immune activation.

EQUOL SUPPLEMENTATION AND ARTERIAL AGING — ACE TRIAL (NIH)

  • NCT05741060 (ACE Trial) is a multicenter NIH-funded study measuring effects of Equol on arterial stiffness, small vessel brain disease, and memory — enrolling healthy volunteers with update logged November 5, 2026.

PREVENAR 20 INFANT SAFETY STUDY — PFIZER

  • Trial NCT06622109 is a Japanese post-market safety surveillance study of the 20-valent pneumococcal conjugate vaccine (PREVENAR 20) in infants aged 2 to 6 months receiving their first dose, monitoring real-world safety under actual clinical practice conditions.

📢 PUBLIC HEALTH

LISTERIA — ONGOING MULTI-FOOD OUTBREAK, U.S.

  • As of October 30, 2026, CDC urged consumers to check refrigerators and freezers for recalled prepared meals linked to an ongoing Listeria outbreak, noting illnesses continue despite product recalls.
  • Earlier updates from September 26, 2026 added 3 additional illnesses and 1 death to the Listeria prepared-foods cluster.

SALMONELLA — MULTIPLE CONCURRENT U.S. OUTBREAKS

  • CDC is tracking simultaneous Salmonella outbreaks linked to backyard poultry (34 sick across 13 states as of April 23, 2026), jalapeños (August 5, 2026), alfalfa sprouts co-linked with E. coli (August 21, 2026), and raw oysters (64 sick across 22 states as of December 23, 2025).

MORINGA LEAF SUPPLEMENT ALERT — EXTENSIVELY DRUG-RESISTANT SALMONELLA

  • CDC flagged extensively drug-resistant Salmonella linked to moringa powder capsules in February 2026, with three hospitalizations; moringa-linked Salmonella outbreaks have now resulted in 65 total cases across 28 states as of January 29, 2026.
  • Consumers are advised to check supplement inventories for any moringa leaf-containing products subject to recall.

CHILDHOOD IMMUNIZATION SCHEDULE UPDATE — CDC

  • On January 4, 2026, Acting CDC Director Jim O'Neill signed a decision memorandum acting on a Presidential directive to update the childhood immunization schedule; separately, the schedule was also updated October 6, 2025, to apply individual-based decision-making to COVID-19 vaccination and enable standalone varicella vaccination for toddlers.
  • ACIP voted on December 5, 2025, to recommend individual-based decision-making for hepatitis B vaccination of infants born to hepatitis B surface antigen-negative mothers, adopted by CDC on December 16, 2025.

COUNTERFEIT ONLINE PHARMACY DRUGS — CDC WARNING REMAINS ACTIVE

  • CDC previously warned of significant public health risk from counterfeit prescription medications purchased through online pharmacies, with pills often containing fentanyl or other undeclared substances.

DRUG OVERDOSE DEATHS — DECLINING

  • Provisional 2024 data from CDC's National Vital Statistics System show a 27 percent decrease in U.S. drug overdose deaths, continuing a trend from the 24 percent decline reported in February 2025.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News
  9. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261106-02-v128 · 2026-11-06 02:01 UTC · pulse.uzylab.com